You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – On Friday, the US Food and Drug Administration announced that it had approved Eli Lilly's selpercatinib (Retevmo) for three RET-driven cancer indications. The drug will be available in specialty pharmacies by next week.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.